Risks for FIBROGEN INC (FGEN)

Here are some interesting risks from the recent filings of FIBROGEN INC. Our algorithms work hard to highlight risks unique to this company.

Risks Related to the Development and Commercialization of Our Product Candidates

Business — Pamrevlumab for the Treatment of Fibrosis and Cancer

We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates.

Business — Roxadustat for the Treatment of Anemia in Chronic Kidney Disease — Limitations of the Current Standard of Care for Anemia in CKD

If we are unable to establish sales, marketing and distribution capabilities or enter into or maintain agreements with third parties to market and sell our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.